Please assess the completion status of the following clinical trial:

Trial Title: Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Meets criteria for 1 of the 4 defined study cohorts~* TNBC, defined as estrogen receptor (ER) and progesterone receptor (PR) negative (\< 1% by immunohistochemistry) and human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization \[FISH\] negative)~* Metastatic disease or locally-advanced disease not amenable to curative intent treatment~* Adequate hepatic, renal, cardiac, and hematologic function~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Recovery to baseline or ≤ Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version.4.0~Key Exclusion Criteria:~* Known brain metastases or central nervous system (CNS) cancer unless adequately treated with radiotherapy and/or surgery and stable for ≥ 2 mo~* Unable to receive oral medications~* Known hypersensitivity to Cremophor®-based agents~* Major surgery within 28 days of Cycle 1 Day 1

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - African ancestry, 3rd line+ (Type: EXPERIMENTAL): Intervention = Paclitaxel- CB-839 (Pac-CB) combination~1. Participants must self-identify as African ancestry (includes African American).~2. At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~   * Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~  * Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo.
- Cohort 2 - African ancestry, 1st line (Type: EXPERIMENTAL): Intervention = Pac-CB combination~1. Participants must self-identify as African ancestry (includes African American).~2. No prior systemic therapy for advanced or metastatic disease.~   * Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was \> 12 mo.
- Cohort 3 - Non-African ancestry, 3rd line+ (Type: EXPERIMENTAL): Intervention = Pac-CB combination~1. Participants do not self-identify as African ancestry.~2. Otherwise have the same criteria as Cohort 1.
- Cohort 4 - Non-African ancestry, 1st line (Type: EXPERIMENTAL): Intervention = Pac-CB combination~1. Participants do not self-identify as African ancestry.~2. Otherwise have the same criteria as Cohort 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).